Precision Medicine-Based Targeted Therapy and Companion Diagnostics

Intelligenix Advanced Diagnostics is a biopharma company developing molecular-based therapeutic compounds and companion diagnostic tests for personalized medicine.

Intelligenix Advanced Diagnostics has licensed patented technology that utilizes unique molecular signatures to detect and predict cancer development years earlier than current clinical tests. Utilizing Artificial Intelligenix (AI)-driven screening creates an 'early warning system' for cancer surveillance of patients, whether they are healthy, at high risk of developing cancer, or being monitored during or after cancer therapy. By utilizing molecular techniques, we are also developing next-generation assays that provide valuable diagnostic information to detect, diagnose, evaluate, and determine the best course of treatment for the patient.

Intelligenix Advanced Diagnostics is also developing therapies that offer more of a cancer-specific therapeutic approach to treating malignancies such as prostate and breast cancer than what can be offered by competitive therapies. By harnessing the power of our precision medicine-based companion diagnostics, we have developed targeted therapeutics that are directed to cancer factors that are specific to the patient, thus increasing positive outcomes.